Haleos Labs Reports FY26 Profit Decline Amid Board Changes

Haleos Labs Ltd (formerly SMS Lifesciences India Limited) reported a decline in financial performance for the year ended March 31, 2026. Standalone revenue from operations decreased by 9.71% to ₹300.99 crore, and net profit fell by 16.82% to ₹17.78 crore.

Consolidated figures also showed a dip, with revenue at ₹333.79 crore and net profit at ₹17.80 crore for the same period.

Reader Takeaway: Profit decline is a concern, but dividend payout offers some shareholder return.

What just happened

Haleos Labs Ltd, formerly SMS Lifesciences India Limited, has announced its financial results for the fiscal year ending March 31, 2026. The company's standalone revenue from operations declined by 9.71% to ₹300.99 crore compared to ₹333.37 crore in the previous fiscal year. Consequently, the standalone net profit saw a significant drop of 16.82%, settling at ₹17.78 crore from ₹21.37 crore.

The consolidated financial results mirrored this trend, with revenue standing at ₹333.79 crore and net profit at ₹17.80 crore.

Why this matters

The decline in both revenue and profit signals potential challenges within the company's operational performance or market conditions. Investors will be keen to understand the reasons behind this contraction and the company's strategies to improve future financial results.

Despite the financial downturn, the Board has recommended a dividend of ₹1.50 per equity share (15% on face value of ₹10), subject to shareholder approval. This indicates a commitment to returning value to shareholders even in a challenging period.

The backstory

Haleos Labs, previously known as SMS Lifesciences India Limited, is involved in the pharmaceutical sector. The company has undergone corporate actions and governance updates alongside its financial reporting.

What changes now

Significant corporate governance changes have been noted. Mrs. Sundaramma Patibandla has resigned as an Independent Director, effective May 29, 2026. This has led to the reconstitution of key board committees, including the Audit, Nomination & Remuneration, and Stakeholders' Relationship Committees.

Furthermore, M/s. Suryanarayana & Suresh have been appointed as the new Statutory Auditors for a term of five years, replacing the previous auditor, M/s. Rambabu & Co., who issued an unmodified audit opinion for FY2026.

Mrs. Sudeepthi Gopineedi has been reappointed as a Whole-time Director for five years, effective from September 2, 2026.

Risks to watch

Investors should closely monitor the reasons for the decline in revenue and profits. The resignation of an independent director could also be a point of concern, depending on the disclosed reasons. The appointment of new auditors requires tracking their performance and opinions in future filings.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• FY2026 Revenue: ₹300.99 crore (Standalone)
• FY2025 Revenue: ₹333.37 crore (Standalone)
• FY2026 Net Profit: ₹17.78 crore (Standalone)
• FY2025 Net Profit: ₹21.37 crore (Standalone)
• Recommended Dividend: ₹1.50 per share

What to track next

Investors should look for management commentary on the reasons for the financial decline, strategies for future growth, and any further developments regarding board composition and auditor performance.